Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
August 18 2020 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W.
Love, M.D., has been appointed to the company’s Board of Directors.
Dr. Love has more than 25 years of global experience in the
healthcare and biotechnology/pharmaceutical industry and currently
serves as President and Chief Executive Officer of Global Blood
Therapeutics.
“We are pleased to welcome Ted to our Board of Directors given
his distinguished industry expertise and leadership,” said Clay
Siegall, Ph.D., President and Chief Executive Officer of Seattle
Genetics. “His extensive experience will be a valued addition at
this transformational time for our company, with three marketed
products, significant development across our pipeline and an
expanding global footprint. We look forward to working with Ted on
our quest to improve the lives of people with cancer through
innovative medicines that address unmet medical needs.”
Concurrent with the appointment of Dr. Love, Srinivas Akkaraju,
M.D., Ph.D., has resigned from the company’s Board of Directors.
Dr. Akkaraju has served as a Director since 2003.
“I want to thank Srini for his incredible contributions over
more than 17 years,” added Dr. Siegall. “He has played an
instrumental role in building Seattle Genetics to the global,
multi-product company that it is today.”
Prior to Dr. Love’s current role at Global Blood Therapeutics,
he held executive positions at a number of biopharmaceutical
companies including Onyx Pharmaceuticals, Nuvelo, Inc. and
Theravance, Inc. Earlier in his career, Dr. Love held a number of
senior management positions at Genentech, where he oversaw the
development strategy and execution that led to the approvals of six
innovative medicines. Dr. Love holds a B.A. in molecular biology
from Haverford College and an M.D. from Yale Medical School. He
completed a residency in internal medicine and a fellowship in
cardiology at the Massachusetts General Hospital. He currently
serves on the board of directors of Royalty Pharma and the
Biotechnology Innovation Organization, and has served as a
consultant in medicine in the Department of Cardiology at the
Massachusetts General Hospital.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that
discovers, develops and commercializes transformative cancer
medicines to make a meaningful difference in people’s lives.
ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab
vedotin-ejfv) use the Company’s industry-leading antibody-drug
conjugate (ADC) technology. ADCETRIS is approved in certain
CD30-expressing lymphomas, and PADCEV is approved in certain
metastatic urothelial cancers. TUKYSA® (tucatinib), a small
molecule tyrosine kinase inhibitor, is approved in certain
HER2-positive metastatic breast cancers. The company is
headquartered in the Seattle, Washington area, with locations in
California, Switzerland and the European Union. For more
information on our robust pipeline, visit www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the extent of
development across the company’s pipeline, the expansion of its
global footprint and its efforts to develop additional cancer
medicines to address unmet medical needs. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the difficulty and uncertainty of pharmaceutical
product development, the risk of adverse events or safety signals,
the inability to show sufficient activity in clinical trials and
the possibility of adverse regulatory actions as product candidates
are evaluated in clinical trials even after promising results in
preclinical research. More information about the risks and
uncertainties faced by Seattle Genetics is contained under the
caption “Risk Factors” included in the Company’s Quarterly Report
on Form 10-Q for the quarter ended June 30, 2020 filed with the
Securities and Exchange Commission. Seattle Genetics disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200818005140/en/
Media: Monique Greer (425) 527-4641 mgreer@seagen.com Investors:
Peggy Pinkston (425) 527-4160 ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024